|
Jul 16
|
Revolution Medicines (RVMD) Gets Initiated With a New Buy Rating at Goldman Sachs
|
|
Jul 2
|
Oppenheimer Reaffirms Outperform on Revolution Medicines, Cites PDAC and NSCLC Trial Progress
|
|
Jun 30
|
Revolution Medicines and Summit Therapeutics Enter Into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors With Ivonescimab in RAS Mutant Tumors
|
|
Mar 3
|
Revolution Medicines, Inc. (RVMD): Among the Cash-Rich Mid Cap Stocks to Buy Now
|
|
Feb 27
|
Q4 2024 Revolution Medicines Inc Earnings Call
|
|
Feb 27
|
Revolution Medicines Inc (RVMD) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ...
|
|
Feb 26
|
Revolution Medicines Reports Fourth Quarter and Full Year 2024 Financial Results and Update on Corporate Progress
|
|
Jun 20
|
Insider Sale: COO Margaret Horn Sells Shares of Revolution Medicines Inc (RVMD)
|
|
May 10
|
Revolution Medicines Reports Q1 2024 Financial Results: Challenges and Strategic Advances in ...
|
|
May 10
|
Revolution Medicines First Quarter 2024 Earnings: US$0.70 loss per share (vs US$0.72 loss in 1Q 2023)
|
|
May 9
|
Revolution Medicines, Inc. (NASDAQ:RVMD) Q1 2024 Earnings Call Transcript
|
|
May 9
|
Revolution Medicines Inc (RVMD) (Q1 2024) Earnings Call Transcript Highlights: Strategic ...
|
|
May 8
|
Revolution Medicines Reports First Quarter 2024 Financial Results and Update on Corporate Progress
|
|
May 4
|
Insider Sale: CFO Jack Anders Sells 10,000 Shares of Revolution Medicines Inc (RVMD)
|
|
May 1
|
Revolution Medicines to Report Financial Results for First Quarter 2024 After Market Close on May 8, 2024
|
|
Apr 9
|
Revolution Medicines Announces Publication on the Discovery of and Translational Research for RMC-6236, an Investigational RAS(ON) Multi-Selective Tri-Complex Inhibitor Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins
|
|
Apr 8
|
Revolution Medicines Announces Publications on the Discovery and Preclinical Profile of Representative of a New Class of RAS(ON) Multi-Selective Inhibitors Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins
|
|
Apr 4
|
Revolution Medicines to Participate in Upcoming Investor Conferences
|
|
Mar 28
|
Revolution Medicines to Deliver Multiple Presentations at the Upcoming American Association for Cancer Research Annual Meeting 2024
|
|
Jan 5
|
Carnival upgraded, PayPal downgraded: Wall Street's top analyst calls
|